PD-L1 mRNA

PD-L1 mRNA (N1-Me-Pseudo UTP) is a mRNA sequence encoding programmed death-ligand 1, which binds PD‑1 to inhibit T‑cell activity and is a key molecule in immune evasion and checkpoint blockade research. This product is ideal for immuno-oncology research, general cancer biology, and immunotherapy biomarker studies, and further be used for screening and validation of delivery formulations or expression systems.

This mRNA features following structure: 

• Cap 1 (N7-methylguanosine Cap) with high capping efficiency 
• Poly(A) tail with 100 consecutive A 
• 5’ and 3’ UTR with proven efficient translation 
• ORF with codon optimization
• N1-methyl-pseudouridine modification

Competitive advantage of AmRNA product:

At AmRNA, we are committed to delivering ready-to-use mRNA of the highest quality standards (only A grade). Each mRNA is produced using state-of-the-art industrial synthesis and purification technologies, ensuring ultra-high purity, capping efficiency, and poly(A) tail integrity. Residual impurities such as protein, DNA, and dsRNA are reduced to trace levels to minimize potential immunogenicity. Our comprehensive quality control panel rigorously verifies every critical attribute to ensure batch-to-batch consistency, ensuring data reproducibility in both in vitro and in vivo applications.